These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2416 related articles for article (PubMed ID: 25546809)

  • 1. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler M; Day JD; Weiss JP; Osborn JS; Muhlestein JB; Anderson JL; Mallender C; Bunch TJ
    Heart Rhythm; 2015 Apr; 12(4):681-6. PubMed ID: 25546809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry.
    Kornej J; Hindricks G; Kosiuk J; Arya A; Sommer P; Husser D; Rolf S; Richter S; Piorkowski C; Gaspar T; Lip GY; Bollmann A
    Circ Arrhythm Electrophysiol; 2013 Oct; 6(5):868-74. PubMed ID: 24047706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHADS2 and CHA2DS2-VASc scores as predictors of left atrial ablation outcomes for paroxysmal atrial fibrillation.
    Letsas KP; Efremidis M; Giannopoulos G; Deftereos S; Lioni L; Korantzopoulos P; Vlachos K; Xydonas S; Kossyvakis C; Sideris A
    Europace; 2014 Feb; 16(2):202-7. PubMed ID: 23813452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of CHADS2, R2CHADS2, and CHA2DS2-VASc scores for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry.
    Kornej J; Hindricks G; Kosiuk J; Arya A; Sommer P; Husser D; Rolf S; Richter S; Huo Y; Piorkowski C; Bollmann A
    Circ Arrhythm Electrophysiol; 2014 Apr; 7(2):281-7. PubMed ID: 24610790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-stroke CHADS2 and CHA2DS2-VASc scores are useful in stratifying three-month outcomes in patients with and without atrial fibrillation.
    Tu HT; Campbell BC; Meretoja A; Churilov L; Lees KR; Donnan GA; Davis SM
    Cerebrovasc Dis; 2013; 36(4):273-80. PubMed ID: 24135809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CHA2DS2-VAS(C) and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation.
    Glotzer TV; Hellkamp AS; Lee KL; Lamas GA
    Can J Cardiol; 2015 Aug; 31(8):1004-11. PubMed ID: 26076964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHADS₂, CHA₂S₂DS₂-VASc, and long-term stroke outcome in patients without atrial fibrillation.
    Ntaios G; Lip GY; Makaritsis K; Papavasileiou V; Vemmou A; Koroboki E; Savvari P; Manios E; Milionis H; Vemmos K
    Neurology; 2013 Mar; 80(11):1009-17. PubMed ID: 23408865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
    Olesen JB; Torp-Pedersen C; Hansen ML; Lip GY
    Thromb Haemost; 2012 Jun; 107(6):1172-9. PubMed ID: 22473219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation.
    Zhu WG; Xiong QM; Hong K
    Tex Heart Inst J; 2015 Feb; 42(1):6-15. PubMed ID: 25873792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial.
    Apostolakis S; Lane DA; Buller H; Lip GY
    Thromb Haemost; 2013 Nov; 110(5):1074-9. PubMed ID: 24048467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHA
    Kim TH; Yang PS; Kim D; Yu HT; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
    Stroke; 2017 Nov; 48(11):2984-2990. PubMed ID: 28939672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Value of the CHADS
    Yang HJ; Wang GJ; Shuai W; Shen CJ; Kong B; Huang H
    J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104143. PubMed ID: 31477449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHADS
    Wu JT; Wang SL; Chu YJ; Long DY; Dong JZ; Fan XW; Yang HT; Duan HY; Yan LJ; Qian P
    J Atheroscler Thromb; 2017 Feb; 24(2):176-184. PubMed ID: 27301462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Puurunen MK; Kiviniemi T; Schlitt A; Rubboli A; Dietrich B; Karjalainen P; Nyman K; Niemelä M; Lip GY; Airaksinen KE
    Thromb Res; 2014 Apr; 133(4):560-6. PubMed ID: 24461143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation.
    Melgaard L; Gorst-Rasmussen A; Lane DA; Rasmussen LH; Larsen TB; Lip GY
    JAMA; 2015 Sep; 314(10):1030-8. PubMed ID: 26318604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukoaraiosis and stroke recurrence risk in patients with and without atrial fibrillation.
    Ntaios G; Lip GY; Lambrou D; Papavasileiou V; Manios E; Milionis H; Spengos K; Makaritsis K; Vemmos K
    Neurology; 2015 Mar; 84(12):1213-9. PubMed ID: 25695964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores.
    Mitchell LB; Southern DA; Galbraith D; Ghali WA; Knudtson M; Wilton SB;
    Heart; 2014 Oct; 100(19):1524-30. PubMed ID: 24860007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CHADS2 and CHA2DS2-VASc scores predict adverse vascular function, ischemic stroke and cardiovascular death in high-risk patients without atrial fibrillation: role of incorporating PR prolongation.
    Chan YH; Yiu KH; Lau KK; Yiu YF; Li SW; Lam TH; Lau CP; Siu CW; Tse HF
    Atherosclerosis; 2014 Dec; 237(2):504-13. PubMed ID: 25463082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients.
    Winkle RA; Mead RH; Engel G; Kong MH; Patrawala RA
    Europace; 2014 Feb; 16(2):195-201. PubMed ID: 24036378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 121.